Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 221

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 221
---
 us to reclassify, restate or otherwise
change or revise our financial statements, including those contained in this Annual Report.

Risks
Related to Our Intellectual Property

If
we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
of our product candidates may be adversely affected.

Our
success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses
of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods
for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from
infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of the date of this
Annual Report, we have filed six patent applications with the U.S. Patent and Trademark Office (the “USPTO”) with respect
to various aspects of our HDAC inhibitor small molecule delivery platforms and Ropidoxuridine, our lead product candidate. However, we
may not be able to apply for patents on certain aspects of our product candidates or delivery technologies in a timely fashion or at
all. To date, four U.S. patents and eighteen European patents have been granted. There is no guarantee that any of our pending patent
applications will result in issued or granted patents, that any of our issued, granted or licensed patents will not later be found to
be invalid or unenforceable or that any issued, granted or licensed patents will include claims that are sufficiently broad to cover
our product candidates or delivery technologies or to provide meaningful protection from our competitors. Moreover, the patent position
of specialty pharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able
to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology
and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties
disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market.

33

The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
requirements during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction